Basilea's Business Strategy Emboldened By $500m Pfizer Deal

Swiss company Basilea has attracted Pfizer as a European partner for its antifungal Cresimba and plans to strengthen its development pipeline with licensed-in products and further collaborations.

Basel Minister by Night
Basel Minster By Night • Source: Shutterstock

Upfront, milestones and royalty payments from Pfizer Inc., the newly recruited European licensee for Basilea Pharmaceutica Ltd.’s antifungal, Cresemba (isavuconazole), should give a welcome boost to the Swiss company’s strategy of developing early clinical-stage products to overcome resistance to anti-infective and oncology medicines, and finding additional partners around the world for its marketed products that include Cresemba and the antibiotic, Zevtera/Mabelio (ceftobiprole).

Basilea has spent the past year or so making Cresemba available in key European markets, including Germany, Italy, the UK,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.